A securities class action has been filed in the USDC – S.D.N.Y. against Actinium Pharmaceuticals, Inc (ATNM) (“Actinium” or the “Company”), on behalf of all persons and entities that purchased or otherwise acquired Actinium securities between October 31, 2022, and August 2, 2024, both dates inclusive (the “Class Period”).
Actinium is a late-stage biopharmaceutical company that is engaged in developing targeted radiotherapies, such as Iomab-B, to improve survival for people who have failed existing oncology therapies. Actinium’s common stock trades on the NYSE American under the symbol “ATNM.”
The Complaint alleges that, throughout the Class Period, the Defendants made materially false and misleading statements that conditioned investors to believe that there was a very high likelihood that the Food and Drug Administration (“FDA”) would review and approve Actinium’s Biologics License Application (“BLA”) for Iomab-B. Specifically, Defendants
(1) repeatedly touted the Phase 3 Sierra trial’s (the “Sierra Trial”) positive Complete Remission (“DCR”) data while downplaying the study’s failure to generate statistically significant or clinically meaningful Overall Survival data; and
(2) misled investors about the importance of the Sierra Trial’s poor Overall Survival data by claiming that the FDA had somehow blessed the design of the Sierra Trial such that the lack of statistically significant or clinically meaningful OS data would not be a barrier to approval of the Biologics License Application (“BLA”).
If you purchased Actinium securities during the Class Period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.